Drugs / OGALVIBART
OGALVIBART
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04700163 | Jan 2021 → Feb 2022 | COVID-19 | Rockefeller University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05393999 | Nov 2021 → Mar 2022 | COVID-19, autoimmune thrombocytopenia, leukemia, plasma cell myeloma +1 | Imperial College Healthcare NHS Trust | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04518410 | Aug 2020 → Apr 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OGALVIBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095319 ↗ |
| Known as | BMS-986414 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04518410 ↗ |
| Known as | C-135-LS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04700163 ↗ |
| Known as | IM051 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095319 ↗ |
| Known as | Ogalvibart component of im-051 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095319 ↗ |
| Modality | Monoclonal antibody | “anti-SARS-CoV-2 mAbs” NCT04700163 ↗ |
| Route | Subcutaneous | “Administered subcutaneously (SC) as 4 separate injections for one dose” NCT04518410 ↗ |